“The COVID-19 pandemic dramatically changed the way that young people interact with one another and offers us an opportunity to examine whether drug taking behavior has shifted through these changes,” said NIDA Director Nora D. Volkow, M.D. “Moving forward, it will be critical to investigate how and when different substances are used among this young population, and the impact of these shifts over time.”
Source: National Institute of Drug Abuse
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more
